UBS analyst Trung Huynh downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Neutral with a price target of $738.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE